Professional · Issue 2 · 2026-09-28
Contraception Counseling Gap Identified Among Adults With Cystic Fibrosis
Editorially reviewed research summaries, context, and limitations.
Kevin P Lonabaugh, HollyAnn Jacobs, Jordan Orofino et al.
Summary: A cross-sectional web-based survey of 97 adult females with cystic fibrosis across the United States and Canada examined contraceptive use patterns, knowledge, and preferences. Despite 90% of respondents not actively trying to conceive, only 55% reported using contraception, revealing a substantial gap between reproductive intent and protective behavior. Most participants (68%) wanted contraceptive guidance from their CF care team, yet fewer than 30% had actually received it. Persistent misconceptions about antibiotic-contraceptive interactions were also documented.
Why it matters: The dramatic improvement in CF survival and quality of life driven by CFTR modulators has transformed reproductive health from a theoretical concern into an immediate clinical priority. Unintended pregnancy in CF carries real risks: CFTR modulator teratogenicity data remain limited, disease burden complicates pregnancy management, and medication adjustments may be required. The finding that nearly half of sexually active women with CF who are not trying to conceive are nonetheless unprotected underscores an actionable gap in routine CF care. The documented misconception about antibiotics reducing contraceptive efficacy is a specific, correctable knowledge deficit that CF pharmacists and clinicians are well-positioned to address.
Expert perspective: This study contributes useful descriptive data to an underexplored area of CF care, but the evidence base has meaningful limitations that temper strong conclusions. The sample of 97 participants is modest, and recruitment through Community Voice and Elevate — online communities affiliated with the Cystic Fibrosis Foundation — introduces self-selection bias. Individuals who voluntarily join a virtual patient community and respond to a reproductive health survey are likely more engaged with their CF care and more comfortable discussing reproductive topics than the broader CF population, meaning the true counseling gap in the general CF population could be even wider than reported here.
The cross-sectional design captures a single point in time and cannot establish whether counseling deficits caused the gaps in contraceptive use, nor whether provider-initiated conversations actually change contraceptive behavior or outcomes. The survey was also limited to females aged 18 and older, so findings cannot be generalized to adolescents or to nonbinary and transgender individuals with CF who may also require contraceptive counseling.
The finding that side-effect profiles were valued more than contraceptive efficacy is clinically interesting and probably underappreciated in routine practice, suggesting that patient-centered contraceptive counseling in CF should lead with tolerability rather than effectiveness rankings. The antibiotic-contraceptive misconception finding deserves particular attention: current evidence does not support a clinically meaningful interaction between most antibiotics commonly used in CF and hormonal contraceptives (rifampin being the notable exception), and correcting this misconception is a concrete, low-cost intervention. CF pharmacists are ideally placed to deliver this counseling. The 28% rate of receiving contraceptive counseling from the CF team is low but not surprising; reproductive health has historically been siloed from CF disease management. This paper provides reasonable justification — even if preliminary — for incorporating standardized reproductive health discussions into CF care protocols, though the field will need larger, more representative studies and ultimately intervention trials to determine whether structured counseling programs translate into better reproductive health outcomes.
Relevance: Cystic Fibrosis
Source: https://pubmed.ncbi.nlm.nih.gov/42670820/
---